Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Small Molecules Studied

  • Page 1 of 4
  • 1 to 25 of 89 Small Molecules
HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10008-3 Sorafenib
BAY-439006
LSM-1008 216239
10013-3 GSK461364
GSK461364A
LSM-1013 15983966
10021-5 Tozasertib
VX680; MK-0457
LSM-1021 5494449
10023-3 Imatinib
Gleevec; Glivec; CGP-57148B; STI-571
LSM-1023 5291
10026-3 PD173074 LSM-1026 1401
10035-2 Sigma A6730
KIN001-102; AKT inhibitor VIII; Akt1/2 kinase inhibitor
LSM-1035 10196499
10048 PD184352
CI-1040
LSM-1048 6918454
10051-3 Lapatinib
GW-572016; Tykerb
LSM-1051 208908
10052-3 Sirolimus
Rapamycin
LSM-1052 5040
10056-2 Selumetinib
AZD6244; Array142886
LSM-1056 10127622
10062-3 GSK1070916
KIN001-216
LSM-1062 46885626
10096-2 ZM-447439 LSM-1096 9914412
10097-3 Erlotinib
OSI-774
LSM-1097 176870
10098-2 Gefitinib
ZD1839; Iressa
LSM-1098 123631
10099-2 Nilotinib
AMN-107
LSM-1099 644241
10102-3 Taxol
Paclitaxel
LSM-1102 441276
10107 MG-132 LSM-1107 462382
10108-2 Geldanamycin LSM-1108 644250
10110-3 FR180204
FR 180204; KIN001-230
LSM-1110 11493598
10133-2 Afatinib
BIBW-2992
LSM-5742 57519523
10136-2 TPCA-1 LSM-1136 9903786
10142-2 Trametinib
GSK-1120212; GSK1120212; GSK1120212B; JTP-74057
LSM-1143 11707110
10146-2 Omipalisib
GSK2126458; GSK2126458A
25167777
10175-3 Sunitinib
Sutent; SU11248
LSM-1176 3086686
10189-2 Bosutinib
SKI-606
LSM-1190 5328940
  • Page 1 of 4
  • 1 to 25 of 89 Small Molecules